Tags

Type your tag names separated by a space and hit enter

Metabolic Syndrome: Polycystic Ovary Syndrome.
FP Essent. 2015 Aug; 435:30-42.FE

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by androgen excess, ovulatory dysfunction, and polycystic ovaries. It is the most common endocrinopathy among women of reproductive age, affecting between 6.5% and 8% of women, and is the most common cause of infertility. Insulin resistance is almost always present in women with PCOS, regardless of weight, and they often develop diabetes and metabolic syndrome. The Rotterdam criteria are widely used for diagnosis. These criteria require that patients have at least two of the following conditions: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. The diagnosis of PCOS also requires exclusion of other potential etiologies of hyperandrogenism and ovulatory dysfunction. The approach to PCOS management differs according to the presenting symptoms and treatment goals, particularly the patient's desire for pregnancy. Weight loss through dietary modifications and exercise is recommended for patients with PCOS who are overweight. Oral contraceptives are the first-line treatment for regulating menstrual cycles and reducing manifestations of hyperandrogenism, such as acne and hirsutism. Clomiphene is the first-line drug for management of anovulatory infertility. Metformin is recommended for metabolic abnormalities such as prediabetes, and a statin should be prescribed for cardioprotection if the patient meets standard criteria for statin therapy.

Authors+Show Affiliations

Department of Internal Medicine at the University of Kansas School of Medicine-Wichita, 1010 North Kansas, Wichita, KS 67214-3199.Department of Family and Community Medicine at the University of Kansas School of Medicine-Wichita, 707 N. Emporia, Wichita, KS 67214.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26280343

Citation

Mortada, Rami, and Tracy Williams. "Metabolic Syndrome: Polycystic Ovary Syndrome." FP Essentials, vol. 435, 2015, pp. 30-42.
Mortada R, Williams T. Metabolic Syndrome: Polycystic Ovary Syndrome. FP Essent. 2015;435:30-42.
Mortada, R., & Williams, T. (2015). Metabolic Syndrome: Polycystic Ovary Syndrome. FP Essentials, 435, 30-42.
Mortada R, Williams T. Metabolic Syndrome: Polycystic Ovary Syndrome. FP Essent. 2015;435:30-42. PubMed PMID: 26280343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic Syndrome: Polycystic Ovary Syndrome. AU - Mortada,Rami, AU - Williams,Tracy, PY - 2015/8/18/entrez PY - 2015/8/19/pubmed PY - 2015/10/31/medline SP - 30 EP - 42 JF - FP essentials JO - FP Essent VL - 435 N2 - Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by androgen excess, ovulatory dysfunction, and polycystic ovaries. It is the most common endocrinopathy among women of reproductive age, affecting between 6.5% and 8% of women, and is the most common cause of infertility. Insulin resistance is almost always present in women with PCOS, regardless of weight, and they often develop diabetes and metabolic syndrome. The Rotterdam criteria are widely used for diagnosis. These criteria require that patients have at least two of the following conditions: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. The diagnosis of PCOS also requires exclusion of other potential etiologies of hyperandrogenism and ovulatory dysfunction. The approach to PCOS management differs according to the presenting symptoms and treatment goals, particularly the patient's desire for pregnancy. Weight loss through dietary modifications and exercise is recommended for patients with PCOS who are overweight. Oral contraceptives are the first-line treatment for regulating menstrual cycles and reducing manifestations of hyperandrogenism, such as acne and hirsutism. Clomiphene is the first-line drug for management of anovulatory infertility. Metformin is recommended for metabolic abnormalities such as prediabetes, and a statin should be prescribed for cardioprotection if the patient meets standard criteria for statin therapy. SN - 2159-3000 UR - https://www.unboundmedicine.com/medline/citation/26280343/Metabolic_Syndrome:_Polycystic_Ovary_Syndrome_ L2 - https://medlineplus.gov/obesity.html DB - PRIME DP - Unbound Medicine ER -